Neutralizing Activity of Anti-interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated With Their Binding Domains.
Adult
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Neutralizing
/ immunology
Autoantibodies
/ chemistry
Binding, Competitive
Epitopes
/ chemistry
Female
Humans
Immunologic Deficiency Syndromes
/ immunology
Interferon-gamma
/ immunology
Male
Mice
Middle Aged
Protein Binding
Protein Domains
adult-onset immunodeficiency
anti-interferon-γ autoantibody
competitive-binding ELISA
interferon-γ
neutralizing antibody
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
04
2019
accepted:
29
07
2019
entrez:
3
9
2019
pubmed:
3
9
2019
medline:
6
10
2020
Statut:
epublish
Résumé
Adult-onset immunodeficiency (AOID) with anti-interferon-γ (IFN-γ) autoantibodies (autoAbs) is an emerging immunodeficiency syndrome in Asian countries. The presence of neutralizing anti-IFN-γ autoAbs are significantly associated with severe disseminated opportunistic infections. However, the characteristics of the neutralizing antibodies in patients are poorly defined. To better understand the properties of the anti-IFN-γ autoAbs in patients with opportunistic infections, a simplified competitive-binding ELISA was developed. The domains recognized by anti-IFN-γ autoAbs were assessed based on their competition with commercial neutralizing mouse anti-IFN-γ monoclonal antibodies (mAbs). First, the binding affinity and neutralizing capacity of these mAbs (clones B27, B133.5, and MD-1) were characterized. Kinetic analysis and epitope binning using bio-layer interferometry showed the comparable binding affinity of these mAbs to full-length IFN-γ and to the adjacent binding region. These mAbs did not recognize the synthetic 20-mer peptides and inhibited IFN-γ-mediated functions differently. In a competitive-binding ELISA, the anti-IFN-γ autoAbs in AOID serum blocked B27, B133.5, and MD-1 mAb binding. This evidence suggested that the autoAbs that competed with neutralizing mouse anti-IFN-γ mAbs recognized a discontinuous epitope of homodimeric IFN-γ as these mAbs. The patient autoAbs that recognized the B27 epitope exhibited strong neutralizing activity that was determined by the functional analysis. Our results demonstrated the heterogeneity of the autoAbs against IFN-γ in AOID patients and the different patterns among individuals. These data expand upon the fundamental knowledge of neutralizing anti-IFN-γ autoAbs in AOID patients.
Identifiants
pubmed: 31474987
doi: 10.3389/fimmu.2019.01905
pmc: PMC6702949
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Autoantibodies
0
Epitopes
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1905Références
Clin Infect Dis. 2004 Jan 1;38(1):e10-4
pubmed: 14679469
J Immunol. 2005 Oct 1;175(7):4769-76
pubmed: 16177125
Cytokine Growth Factor Rev. 2009 Apr;20(2):97-113
pubmed: 19268625
Cytokine. 2010 Apr;50(1):1-14
pubmed: 20036577
Infection. 2011 Feb;39(1):65-71
pubmed: 21128092
Blood. 2012 Apr 26;119(17):3933-9
pubmed: 22403254
N Engl J Med. 2012 Aug 23;367(8):725-34
pubmed: 22913682
PLoS One. 2013 Sep 27;8(9):e76371
pubmed: 24086734
Clin Infect Dis. 2014 Mar;58(6):e115-8
pubmed: 24336756
Mol Immunol. 1989 Jan;26(1):17-25
pubmed: 2467194
Semin Immunol. 2014 Dec;26(6):454-70
pubmed: 25453225
J Immunol Methods. 1985 May 23;79(2):293-305
pubmed: 2582059
Clin Infect Dis. 2016 Mar 15;62(6):770-773
pubmed: 26646678
Clin Infect Dis. 2016 Aug 15;63(4):572-3
pubmed: 27225240
J Interferon Cytokine Res. 2016 Sep;36(9):542-51
pubmed: 27336613
Nat Med. 2016 Sep;22(9):994-1001
pubmed: 27525523
Clin Microbiol Infect. 2018 Feb;24(2):159-165
pubmed: 28694201
J Clin Immunol. 2017 Oct;37(7):644-649
pubmed: 28779413
Clin Infect Dis. 2018 Apr 3;66(8):1239-1245
pubmed: 29126235
Exp Biol Med (Maywood). 2018 Apr;243(7):621-626
pubmed: 29512397
Intern Med. 2018 Oct 15;57(20):3041-3045
pubmed: 29780147
J Exp Med. 1986 Jul 1;164(1):263-79
pubmed: 3088195
Sci Rep. 2019 Apr 5;9(1):5682
pubmed: 30952894
J Biol Chem. 1994 Jun 10;269(23):16159-62
pubmed: 8206916